BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28880238)

  • 21. Polymorphisms in ATP-binding cassette transporter genes and interaction with diet and life style factors in relation to colorectal cancer in a Danish prospective case-cohort study.
    Kopp TI; Andersen V; Tjonneland A; Vogel U
    Scand J Gastroenterol; 2015; 50(12):1469-81. PubMed ID: 26109419
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
    Lin F; Marchetti S; Pluim D; Iusuf D; Mazzanti R; Schellens JH; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2013 Apr; 19(8):2084-95. PubMed ID: 23461902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
    Ma L; Liu T; Jin Y; Wei J; Yang Y; Zhang H
    Tumour Biol; 2016 Sep; 37(9):12889-12896. PubMed ID: 27449042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer.
    Ikai A; Watanabe M; Sowa Y; Kishimoto M; Yanagisawa A; Fujiwara H; Otsuji E; Sakai T
    Int J Oncol; 2016 Mar; 48(3):1297-304. PubMed ID: 26783196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
    Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
    Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
    Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
    Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
    Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.
    Han JY; Lim HS; Yoo YK; Shin ES; Park YH; Lee SY; Lee JE; Lee DH; Kim HT; Lee JS
    Cancer; 2007 Jul; 110(1):138-47. PubMed ID: 17534875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.
    Tuy HD; Shiomi H; Mukaisho KI; Naka S; Shimizu T; Sonoda H; Mekata E; Endo Y; Kurumi Y; Sugihara H; Tani M; Tani T
    Oncol Lett; 2016 Oct; 12(4):2752-2760. PubMed ID: 27698852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
    De Mattia E; Toffoli G; Polesel J; D'Andrea M; Corona G; Zagonel V; Buonadonna A; Dreussi E; Cecchin E
    Pharmacogenet Genomics; 2013 Oct; 23(10):549-57. PubMed ID: 24018773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
    Shishido Y; Ueno S; Yamazaki R; Nagaoka M; Matsuzaki T
    Anticancer Res; 2013 Apr; 33(4):1379-86. PubMed ID: 23564776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride.
    Takara K; Kitada N; Yoshikawa E; Yamamoto K; Horibe S; Sakaeda T; Nishiguchi K; Ohnishi N; Yokoyama T
    Cancer Lett; 2009 Jun; 278(1):88-96. PubMed ID: 19201079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
    Huang HC; Mallidi S; Liu J; Chiang CT; Mai Z; Goldschmidt R; Ebrahim-Zadeh N; Rizvi I; Hasan T
    Cancer Res; 2016 Mar; 76(5):1066-77. PubMed ID: 26719532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
    Su Y; Lee SH; Sinko PJ
    Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.
    Shah MA; Kemeny N; Hummer A; Drobnjak M; Motwani M; Cordon-Cardo C; Gonen M; Schwartz GK
    Clin Cancer Res; 2005 May; 11(9):3296-302. PubMed ID: 15867226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic interactions in mice between irinotecan and MBL-II-141, an ABCG2 inhibitor.
    Hénin E; Honorat M; Guitton J; Di Pietro A; Payen L; Tod M
    Biopharm Drug Dispos; 2017 Jul; 38(5):351-362. PubMed ID: 28207160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.